Oncology

Patients with breast cancer who are more rational may strongly consider contralateral mastectomy.

Up to 1.3 million women may not be receiving genetic testing to detect BRCA 1/2 mutations, which increase the risk of certain cancer types.

Self-administered acupressure found to improve sleep and daytime alertness among breast cancer survivors.

Patients with psychological and substance use problems are less likely to stay engaged in hepatitis C care.

The findings highlight the role of Tregs in suppressing the immune response.

Targeting the arginase 2 enzyme observed to reduce the growth of pancreatic cancer.

Tisagenlecleucel (Kymriah) is a personalized genetically-modified autologous T cell immunotherapy designed to use a patient’s own T cells to target and kill leukemia.

Tisagenlecleucel is indicated for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia.

Statins may provide a protective effect against breast cancer development.

Scientists hone in on personalized treatments for patients with cancer.

Top news of the day from across the health care landscape.

An estimated 1.2 million American women would likely benefit from recommended genetic test to assess their risk of cancer.

The risk of developing liver cancer is similar with direct-acting antiviral drugs or interferon therapy for hepatitis C virus.

Alcohol consumption results in more than $150 million spent on breast cancer annually.

FDA to evaluate obinutuzumab (Gazyva) in combination with chemotherapy for patients with previously untreated follicular lymphoma.

Experimental drug shows evidence of lowering cholesterol, reducing risk of cardiovascular disease, and potentially treating lung cancer.

Fulvestrant is a hormonal therapy that targets the estrogen receptor and helps slow cancer growth.

Faslodex reduced disease progression by 20% among women with HR+, HER2- advanced breast cancer.

A drug being explored as a cardiovascular disease treatment may also reduce the risk of lung cancer.

A decision on the approval of obinutuzumab is expected by December 23, 2017.

Top news of the day from across the health care landscape.

Hormone therapy is recommended to treat menopause symptoms, but is not recommended for breast cancer survivors.

Women who worked the night shift found to have a greater risk of developing breast cancer.

Breast cancer treatment may cause women to enter menopause prematurely.

Top news of the day from across the health care landscape.

A first-in-class selective retinoic acid receptor alpha agonist is being tested in phase 2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome.

Novel first-in-class selective retinoic acid receptor alpha agonist inhibits tumor growth in acute myeloid leukemia.

T cell responses in different tumor models are fundamentally similar.